IL1A and histiocytic sarcoma: Bermekimab, an inhibitor of IL1α, has yielded good results in phase II open-label studies in HS patients—even after failure to anti-TNF therapy—with significant reductions in inflammatory lesions and no significant drug-related adverse events [91,92,93].